INTRODUCTION
============

Early detection of at-risk populations with decreased kidney function is important for both acute kidney injury and chronic kidney disease (CKD) \[[@B1][@B2][@B3]\]. Glomerular filtration rate (GFR) is the most widely used index for assessing kidney function, which is implicated in the guidelines for CKD diagnosis and staging \[[@B3][@B4][@B5][@B6]\]. Various equations for estimating GFR (eGFR) have been introduced and are currently used; among them, 83% of clinical laboratories used the serum creatinine (Cr)-based Modification of Diet in Renal Disease (MDRD) Study equation in the 2013 College of American Pathologists survey \[[@B7]\]. However, the equation was derived from subjects with CKD, and had the limitation of systematically underestimating GFR in healthy individuals with GFR ≥60 mL/min/1.73 m^2^ \[[@B8][@B9]\]. To overcome this limitation, the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI~Cr~) was developed in 2009 on the basis of serum Cr, and more accurate calculations for GFRs ≥60 mL/min/1.73 m^2^ were made possible \[[@B10]\]. In addition, CKD-EPI 2012 equations based on cystatin C (CysC) (CKD-EPI~CysC~) or a combination of Cr and CysC (CKD-EPI~Cr-CysC~) were proposed in a standardized assay to better estimate GFR \[[@B11][@B12]\]. Another new equation, the revised Lund-Malmö (LM~Revised~) equation was recently developed, and its performance was reported to be more consistent than the MDRD Study and CKD-EPI equations \[[@B13][@B14][@B15]\]. However, this equation was derived from only a Swedish Caucasian population.

There have been several reports that compared the MDRD Study and CKD-EPI equations in the general population \[[@B16][@B17][@B18][@B19][@B20]\]; however, only a few studies have included the CysC-containing equations. In this study, we compared five eGFR equations (MDRD Study equation, LM~Revised~ equation, and three CKD-EPI equations) to explore the differences in the equations across the GFR categories in Korean adults.

METHODS
=======

1. Study population
-------------------

During the year 2014, the recipients of annual physical check-ups at the Gangnam branch of Korean Association of Health Promotion (KAHP, Seoul, Korea) were consecutively included according to the following criteria: over 30 yr old and presence of serum Cr and/or CysC results. There were no exclusion criteria for the subject selection process. KAHP is a specialized health-screening center, which provides routine medical check-ups to over 1,000,000 individuals annually in 16 branch clinics nationwide in Korea.

The number of subjects with serum Cr and CysC results was 1,482 (51 \[42-59\] yr, 48.9% males). Besides serum Cr and/or CysC results, lipid profiles and HbA1c levels were also collected. We conducted a retrospective analysis of laboratory data using the five eGFR equations, and this study was approved by the Institutional Review Board of KAHP.

2. Estimation of GFR
--------------------

GFR (mL/min/1.73 m^2^) was estimated by using five different equations (MDRD Study, LM revised, and three CKD-EPI equations) as follows:

a\) Four-variable MDRD Study equation \[[@B9]\], GFR=175×sCr^-1.154^×Age^-0.203^×0.742 (if female);

b\) LM~Revised~ equation \[[@B13]\], GFR=e^X-0.0158×Age+0.438×ln(Age)^, where ln is natural logarithm and X=2.50+0.0121×(150-sCr) for females with sCr level \<150 µmol/L, 2.50-0.926×ln (sCr/150) for females with sCr level ≥150 µmol/L, 2.56+0.00968×(180-sCr) for males with sCr level \<180 µmol/L, and 2.56-0.926×ln (sCr/180) for males with sCr level ≥180 µmol/L;

c\) CKD-EPI~Cr~ equation \[[@B10]\], GFR=141×min (sCr/κ, 1)^α^× max (sCr/κ, 1)^-1.209^×0.993^Age^×1.018 \[if female\], where sCr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min is the minimum of sCr/κ or 1, and max is the maximum of sCr/κ or 1;

d\) CKD-EPI~CysC~ equation \[[@B11]\], GFR=133×min (sCysC/0.8, 1)^-0.499^×max (sCysC/0.8, 1)^-1.328^×0.996^Age^×0.932 \[if female\], where sCysC is serum cystatin C, min indicates the minimum of sCysC/0.8 or 1, and max indicates the maximum of sCysC/0.8 or 1;

e\) CKD-EPI~Cr-CysC~ equation \[[@B11]\], GFR=135×min (sCr/κ, 1)^α^× max (sCr/κ, 1)^-0.601^×min (sCysC/0.8, 1)^-0.375^×max (sCysC/0.8, 1)^-0.711^×0.995^Age^×0.969 \[if female\], where Scr is serum creatinine, sCysC is serum cystatin C, κ is 0.7 for females and 0.9 for males, α is -0.248 for females and -0.207 for males.

Serum Cr levels were determined by the kinetic Jaffe method using SICDIA CRE reagent (Shinyang Chemical, Seoul, Korea) on an automated chemistry analyzer (HITACHI 7600-110; Hitachi High-Technologies Co., Tokyo, Japan). Isotope-dilution mass spectrometry (IDMS)-traceable calibration was conducted weekly with a C.f.a.s. calibrator (Roche Diagnostics, Indianapolis, IN, USA). For internal quality control in the Cr assay, two levels of Lyphochek assayed chemistry quality control materials (Bio-Rad, Hercules, CA, USA) were tested once a day. The mean within-laboratory precision of the serum Cr assay was 2.1% during the study period. The laboratory participated in the external proficiency testing program organized by the Korean Association of Quality Assurance for Clinical Laboratory, and the results were all acceptable (variance index scores \<150) during 2014.

Serum CysC levels were measured by the latex immunoturbidimetric method using Sekisui reagent (Sekisui Chemical, Tokyo, Japan) on the same analyzer. The reagent was traceable to the European Reference Material DA471/IFCC. Two levels of Liquichek Immunology Control materials (Bio-Rad) were tested once a day. The mean within-laboratory precision of the serum CysC assay was 1.4% during the study period. The inter-laboratory comparison was performed for CysC, and the differences in results between the two locations were within 10%. All measurements were performed according to the manufacturer\'s in structions and standard laboratory procedures.

3. GFR categories
-----------------

GFRs were categorized into ≥90 (G1), 60-89 (G2), 45-59 (G3a), 30-44 (G3b), 15-29 (G4), and \<15 (G5) mL/min/1.73 m^2^ according to the Kidney Disease Improving Global Outcomes (KDIGO) 2012 guideline \[[@B4]\]. The prevalence of reduced GFR, defined as eGFR \<60 mL/min/1.73 m^2^, was compared among the equations on the basis of the levels of serum Cr, CysC, or both \[[@B4]\].

4. Statistical analyses
-----------------------

The eGFR~MDRD~ was regarded as the comparative GFR for com-parisons. Bland-Altman plots were used to identify mean differences and 95% limits of agreement of eGFRs between each equation and the MDRD Study equation. Pearson\'s correlation coefficients (r) were calculated to compare the equations. r coefficients ≤0.35 were considered low or weak correlations; 0.36-0.67, modest or moderate correlations; and 0.68-1.0, strong or high correlations; with r coefficients ≥0.90 being very high correlations \[[@B21]\].

Categorical agreement rates were calculated when eGFR~MDRD~ and eGFR based on other equations were within the same GFR categories. Weighted kappa value was determined to evaluate the degree of categorical agreement, and kappa value was determined for diagnostic agreement with GFR cutoffs of 60 mL/min/1.73 m^2^ and 45 mL/min/1.73 m^2^ \[[@B4]\]. The kappa values were interpreted as follows: \<0.20, poor; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, good; and \>0.81, very good \[[@B22]\]. In general, reduced GFR is defined as an eGFR \<60 mL/min/1.73 m^2^. Additionally, the KDIGO guideline recommends measuring CysC in adults with an eGFR~Cr~ of 45-59 mL/min/1.73 m^2^, who do not have markers of kidney damage for confirmation of CKD \[[@B4]\]. Thus, we used two GFR cutoff points. The overall concordance rate (positive and negative) was also calculated for all equations.

Data were analyzed by using Analyse-it (Analyse-it Software Ltd., Leeds, UK) and MedCalc Statistical Software version 15.2.2 (MedCalc Software, Ostend, Belgium). *P* values ≤0.05 were considered statistically significant.

RESULTS
=======

1. GFR category distribution in the study population
----------------------------------------------------

The baseline subject characteristics and calculated eGFR stratified by age groups are shown in [Table 1](#T1){ref-type="table"}. The CKD-EPI equations yielded higher mean eGFRs than the MDRD Study equation, and the degree of difference varied with the equations and age groups. The eGFR~CKD-EPI\ CysC~ (104.7 mL/min/1.73 m^2^) was the highest, followed by eGFR~CKD-EPI\ Cr-CysC~ (94.0 mL/min/1.73 m^2^), eGFR~CKD-EPI\ Cr~ (81.4 mL/min/1.73 m^2^), eGFR~LM\ Revised~ (74.5 mL/min/1.73 m^2^), and eGFR~MDRD~ (73.5 mL/min/1.73 m^2^). In older patients (≥ 60 yr), the LM~Revised~ equation yielded a lower eGFR than the MDRD Study equation. For all equations, a decreasing eGFR trend was observed as age increased.

The frequencies of the subjects in each GFR category are shown in [Table 2](#T2){ref-type="table"}. The proportion of each GFR category varied considerably between equations, especially for categories G1 and G2. The proportions of G1 were 8.0% (MDRD), 28.0% (CKD-EPI~Cr~), 81.7% (CKD-EPI~CysC~), 66.2% (CKD-EPI~Cr-CysC~), and 7.4% (LM~Revised~), and the proportions of G2 were 82.5% (MDRD), 66.3% (CKD-EPI~Cr~), 15.8% (CKD-EPI~CysC~), 31.1% (CKD-EPI~Cr-CysC~), and 84.6% (LM~Revised~).

2. Concordance between MDRD Study equation and other equations
--------------------------------------------------------------

Categorical agreement rates between the MDRD Study and other equations ranged from 20.3 to 93.8%. Upward reclassification from G2 (MDRD Study equation) to G1 (CKD-EPI equations) was common, especially for CKD-EPI~CysC~ and CKD-EPI~Cr-CysC~ equations ([Table 3](#T3){ref-type="table"}). Weighted kappa values were fair to good in serum Cr-based equations, but poor in CysC-containing equations.

For diagnostic agreement, kappa values at two eGFR cutoffs were variable depending on the equation. Kappa values were better at cutoff 45 mL/min/1.73 m^2^ than 60 mL/min/1.73 m^2^. For all equations, overall concordance rates were greater than 90% when the GFR cutoff of 60 mL/min/1.73 m^2^ was used (96.2% for CKD-EPI~Cr~, 91.6% for CKD-EPI~CysC~, 93.1% for CKD-EPI~Cr-CysC~, and 95.8% for LM~Revised~), or when 45 mL/min/1.73 m^2^ was used (99.9% for CKD-EPI~Cr~, 98.5% for CKD-EPI~CysC~, 98.9% for CKD-EPI~Cr-CysC~, and 99.9% for LM~Revised~).

The mean eGFR difference (calculated by: GFR by MDRD Study equation-GFR by other equations) was largest in the CKD-EPI~CysC~ equation (-31.4, [Fig. 1](#F1){ref-type="fig"}); it was significantly larger than the differences of other equations compared with the MDRD Study equation (*P*\<0.001). The r coefficients were 0.936 for LM~Revised~, 0.972 for CKD-EPI~Cr~, 0.494 for CKD-EPI~CysC~, and 0.806 for CKD-EPI~Cr-CysC~ equations (*P*\<0.001).

3. Prevalence of reduced eGFR
-----------------------------

The prevalence of reduced GFR (\<60 mL/min/1.73 m^2^, which corresponds to GFR categories G3a-G5) according to the age group and gender are presented in [Table 4](#T4){ref-type="table"}. In total, the prevalence of reduced GFR was the highest according to the MDRD Study equation (9.4%) and the lowest (2.4%) according to the CKD-EPI~CysC~ equation. The prevalence increased as age increased in all equations. Of note, a very high percentage of low GFR (45.9%) was noted in patients in their 70\'s according to the LM~Revised~ equation.

DISCUSSION
==========

The Cr-based CKD-EPI equation is recommended for the initial assessment of GFR, and CysC-based CKD-EPI equations can be used for confirmation of kidney disease according to the KDIGO guidelines \[[@B4][@B23]\]. In this study, we compared five eGFR equations, including CysC-based formulas, in the Korean population. The prevalence of reduced GFR by CysC-based CKD-EPI equations has not been reported in Korea yet.

The eGFR classification differed considerably according to the equation used for estimation, especially between CKD-EPI~CysC~ or CKD-EPI~Cr-CysC~ equations compared with the MDRD Study equation. Most of the study population (\>80%) were in the G2 category (60-89 mL/min/1.73 m^2^) according to the MDRD Study equation, but in G1 (≥90 mL/min/1.73 m^2^) according to the CKD-EPI~CysC~ equation. The reason for this discrepancy might be related to the eGFR distribution of the study population. Mean eGFR~MDRD~ was 73.5 mL/min/1.73 m^2^ with a standard deviation of 12.2 mL/min/1.73 m^2^; thus, there were many results around the cutoff value of 90 mL/min/1.73 m^2^. In addition, the CKD-EPI~CysC~ and CKD-EPI~Cr-CysC~ equations yielded systematically higher eGFR results (mean difference 31.4 mL/min/1.73 m^2^ and 20.6 mL/min/1.73 m^2^, respectively) in comparison with the MDRD Study equation. This finding was in line with previous studies. In the US National Health and Nutrition Examination Survey (NHANES) 1999-2002 data, the distribution of eGFR~CKD-EPI~ CysC was broader and shifted to the right compared with that of eGFR~MDRD~ \[[@B24]\]. Thus, upward reclassification might be common in CysC-based equations.

All equations, except for the CKD-EPI~CysC~ equation, showed good correlation with the MDRD Study equation. CKD-EPI~CysC~ showed only a moderate correlation (r=0.49). The three different CKD-EPI equations showed an overall low prevalence of reduced GFR compared with the MDRD Study equation, especially according to the two CysC-containing equations. The LM~Revised~ equation was recently reported to outperform the MDRD Study and CKD-EPI equations in a Swedish population \[[@B15]\]; however, there has been no evaluation of this equation in the Asian population. It yielded similar mean eGFR results compared with the MDRD Study equation; these two equations showed a very high correlation and a similar prevalence of reduced GFR. However, eGFR was underestimated in patients ≥ 60 yr, when using the LM~Revised~ equation. This observation needs to be subjected to further studies because of the increased possibility of co-morbidities in older patients. The LM~Revised~ equation was generated only from the Swedish population; hence, ethnic differences might have influenced GFR estimation as well.

Although the CKD-EPI~Cr~ equation is recommended by KDIGO for initial GFR assessment, newer GFR estimating equations have been developed and validated, including a Korean version of the CKD-EPI~Cr~ equation \[[@B25]\], a serum Cr-based full age spectrum equation \[[@B26]\], and a CysC-based equation based on a Caucasian, Asian, pediatric, and adult population (CAPA) \[[@B27]\]. Our study did not aim to compare all recent equations; however, we analyzed the CysC-based CAPA equation briefly. The mean eGFR~CAPA~ (106.3 mL/min/1.73 m^2^), eGFR difference in comparison with MDRD Study equation (-32.9), and prevalence of eGFR less than 60 mL/min/1.73 m^2^ (2.7%) were similar when compared with CKD-EPI~CysC~ equation.

The prevalence of reduced GFR has been reported differently depending on the study population and the GFR-estimating equation used. In several previous studies, there were clinically significant differences in the prevalence of stage 3 or higher CKD depending on the equation used to estimate GFR. Delanaye et al \[[@B20]\] reported that the prevalence of eGFR less than 60 mL/min/1.73 m^2^ was the highest for eGFR~MDRD~ (13%), intermediate for eGFR~CKD-EPI\ Cr~ (9.8%), and the lowest for eGFR~CKD-EPI\ Cr-CysC~ (5%) and eGFR~CKD-EPI\ CysC~ (4.7%) in 4,189 Belgian patients over 50 yr old. This prevalence trend was similar to ours. One Japanese study showed a 2-fold difference of prevalence between the MDRD Study and CKD-EPI~Cr~ equations (12.8 vs 6.5%), by studying over 26,000 participants who underwent annual health check-ups \[[@B16]\]. Lujambio et al \[[@B28]\] reported that the prevalence of eGFR less than 60 mL/min/1.73 m^2^ was the highest for eGFR~CKD-EPI\ CysC~ (21.8%), intermediate for eGFR~CKD-EPI\ Cr-CysC~ (11.8%), and the lowest for eGFR~MDRD~ (5.9%) and eGFR~CKD-EPI\ Cr~ (3.4%) in 119 Uruguayans.

In the US, the prevalence of reduced GFR (eGFR \<60 mL/min/1.73 m^2^) by CKD-EPI~Cr~ equation was reported to be 4.7% from 1988-1994 and 6.5% from 1999-2002 from NHANES data \[[@B29]\]. In Korea, the prevalence of reduced GFR by the CKD-EPI~Cr~ equation has been reported as 7.7% in 2007 and 2.6% in 2010 from Korea NHANES data \[[@B17][@B18]\]. In this study, it was 5.1% of the whole study population. This difference could be due to the following reasons. First, the proportion of younger individuals under 40 yr old was lower than that in other studies (23% vs 30-32%). Compared with 2010 Korea NHANES data, the mean eGFR was relatively lower in this study (81.4 mL/min/1.73 m^2^ vs 95.9-96.8 mL/min/1.73 m^2^), resulting in higher prevalence of reduced GFR compared with other studies. Second, the study period was different (2014 vs 2007-2010), although the impact of this on the prevalence is still uncertain.

Our retrospective study has several limitations. First, we com-pared all the eGFR equations to the MDRD Study equation, because of the absence of GFR data measured by the gold standard method \[[@B18]\]. Therefore, it was impossible to evaluate the accuracy. The magnitude of bias, calculated by measured GFR-calculated GFR was previously reported to be 2.5-5.8 mL/min/1.73 m^2^, and this difference could influence the prevalence of CKD stages \[[@B17][@B24]\]. Second, our population might not be representative of the entire population of Korea. Third, we could not analyze albuminuria data or other markers of kidney damage. The classification of CKD was not performed, which is based on both GFR category and albuminuria category. Thus, there could be the CKD patients among the subjects with eGFR ≥60 mL/min/1.73 m^2^.

In conclusion, this is the first study that compared five eGFR equations in the Korean population. Our data demonstrated remarkable differences in GFR assessment depending on the equation used. The proportion of each GFR category varied considerably, and CysC-containing equations yielded higher eGFRs and showed larger differences compared with the MDRD Study equation. The prevalence of reduced GFR was lowered by the CKD-EPI equations. Further studies using prospective design and in various ethnicities are necessary.

This study was supported by Konkuk University in 2016.
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###### Baseline subject characteristics and estimated glomerular filtration rates stratified by age group
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  -----------------------------------------------------------------------------------------------------------------------------------
  Variables                                   30--39 yr\     40--49 yr\     50--59 yr\     60--69 yr\    70--79 yr\    Total\
                                              N = 275        N = 412        N = 432        N = 289       N= 74         N = 1,482
  ------------------------------------------- -------------- -------------- -------------- ------------- ------------- --------------
  Male %                                      46.7           55.0           45.4           47.4          49.0          48.9

  Age (yr)                                    35 (32--38)    44 (42--46)    54 (52--57)    63(61--66)    72 (70--75)   51 (42--59)

  Body mass index (kg/m^2^)                   22.9 ± 3.8     23.7 ± 3.6     23.6 ± 3.1     23.9 ± 2.9    24.0 ± 3.2    23.6 ± 3.4

  HbA1c (%)^\*^                               5.3 ± 0.4      5.6 ± 1.0      5.7 ± 0.8      6.0 ± 1.0     6.2 ± 1.5     5.7 ± 0.9

  Total cholesterol (mg/dL)                   190 ± 44       198 ± 46       204 ± 71       202 ± 78      195 ± 55      199 ± 61

  Triglyceride (mg/dL)                        95 ± 82        117 ± 102      101 ± 78       102 ± 62      106 ± 57      105 ± 83

  HDL-cholesterol (mg/dL)                     51 ± 14        49 ± 13        51 ± 17        50 ± 19       49 ± 15       50 ± 16

  LDL-cholesterol (mg/dL)                     116 ± 32       123 ± 33       133 ± 54       134 ± 62      122 ± 41      127 ± 47

  Serum Cr (mg/dL)                            0.95 ± 0.20    0.97 ± 0.17    0.96 ± 0.23    0.99 ± 0.35   1.03 ± 0.25   0.97 ± 0.24

  Serum CysC (mg/L)                           0.71 ± 0.14    0.73 ± 0.13    0.78 ± 0.15    0.86 ± 0.21   0.96 ± 0.23   0.78 ± 0.17

  eGFR~MDRD~ (mL/min/1.73 m^2^)               80.1 ± 12.0    75.4 ± 10.2    72.0 ± 10.8    68.9 ± 12.6   64.4 ± 14.4   73.5 ± 12.2

  eGFR~LM\ revised~ (mL/min/1.73 m^2^)        82.9 ± 9.8     78.6 ± 8.8     73.2 ± 9.2     66.8 ± 10.7   58.9 ± 11.9   74.5 ± 11.6

  eGFR~CKD-EPI\ Cr~ (mL/min/1.73 m^2^)        92.1 ± 13.6    85.2 ± 11.7    79.1 ± 11.8    73.0 ± 13.2   65.8 ± 15.0   81.4 ± 14.5

  eGFR~CKD-EPI\ CysC~ (mL/min/1.73 m^2^)      117.8 ± 12.7   112.5 ± 12.4   102.5 ± 14.1   91.0 ± 17.3   79.5 ± 19.1   104.7 ± 18.0

  eGFR~CKD-EPI\ Cr-CysC~ (mL/min/1.73 m^2^)   106.1 ± 13.1   99.9 ± 11.8    91.7 ± 12.1    82.7 ± 14.6   73.2 ± 16.8   94.0 ± 15.9
  -----------------------------------------------------------------------------------------------------------------------------------

All data except male % and age are expressed as mean±standard deviation. Age is presented as median value (25th and 75th percentiles).

^\*^HbA1c was measured in 1,082 participants.

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; LM, Lund-Malmö; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; CysC, cystatin C.

###### Frequency of glomerular filtration rate categories by five estimating equations
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  GFR category (mL/min/1.73 m^2^)   Number (%) of subjects with each GFR category according to the estimating equations                                                                   
  --------------------------------- ------------------------------------------------------------------------------------- --------------- --------------- --------------- --------------- ---------------
  G1                                ≥ 90                                                                                  119 (8.0)       416 (28.0)      1,212 (81.8)    982 (66.2)      109 (7.4)
  G2                                60--89                                                                                1,224 (82.5)    983 (66.3)      235 (15.8)      461 (31.1)      1,254 (84.6)
  G3a                               45--59                                                                                112 (7.5)       58 (3.9)        24 (1.6)        26 (1.8)        92 (6.2)
  G3b                               30--44                                                                                20 (1.3)        18 (1.2)        10 (0.7)        11 (0.7)        14 (0.9)
  G4                                15--29                                                                                6 (0.4)         6 (0.4)         1 (0.0)         2 (0.1)         12 (0.8)
  G5                                \< 15                                                                                 1 (0.1)         1 (0.1)         0 (0.0)         0 (0.0)         1 (0.1)
  Total                                                                                                                   1,482 (100.0)   1,482 (100.0)   1,482 (100.0)   1,482 (100.0)   1,482 (100.0)

Abbreviations: GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; LM, Lund-Malmö; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; CysC, cystatin C.

###### Agreement between MDRD Study equation and other equations
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                     GFR category   MDRD Study   Categorical agreement   Diagnostic agreement at specific eGFR cutoffs                                                                            
  ------------------ -------------- ------------ ----------------------- ----------------------------------------------- ------- ------- ------- ------- ------ ---------------- ---------------- ----------------
  CKD-EPI~Cr~        G1             **119**      297                     0                                               0       0       0       416     76.0   0.521\           0.729\           0.961\
                                                                                                                                                                (0.474--0.568)   (0.662--0.796)   (0.907--1.000)

  G2                 0              **927**      56                      0                                               0       0       983                                                      

  G3a                0              0            **56**                  02                                              0       0       58                                                       

  G3b                0              0            0                       **18**                                          0       0       18                                                       

  G4                 0              0            0                       0                                               **6**   0       6                                                        

  G5                 0              0            0                       0                                               0       **1**   1                                                        

  CKD-EPI~CysC~      G1             **113**      1,047                   43                                              7       2       0       1,212   20.3   0.067\           0.259\           0.415\
                                                                                                                                                                (0.047--0.087)   (0.173--0.346)   (0.217--0.613)

  G2                 4              **169**      54                      4                                               4       0       235                                                      

  G3a                2              7            **13**                  2                                               0       0       24                                                       

  G3b                0              1            2                       **6**                                           0       1       10                                                       

  G4                 0              0            0                       1                                               **0**   0       1                                                        

  G5                 0              0            0                       0                                               0       **0**   0                                                        

  CKD-EPI~Cr-CysC~   G1             **113**      865                     4                                               0       0       0       982     33.3   0.139\           0.402\           0.595\
                                                                                                                                                                (0.111--0.167)   (0.313--0.492)   (0.415--0.776)

  G2                 6              **358**      92                      5                                               0       0       461                                                      

  G3a                0              1            **15**                  7                                               3       0       26                                                       

  G3b                0              0            1                       **7**                                           3       0       11                                                       

  G4                 0              0            0                       1                                               **0**   1       2                                                        

  G5                 0              0            0                       0                                               0       **0**   0                                                        

  LM~revised~        G1             **103**      6                       0                                               0       0       0       109     93.8   0.823\           0.737\           0.962\
                                                                                                                                                                (0.788--0.859)   (0.674--0.799)   (0.910--1.000)

  G2                 16             **1,197**    41                      0                                               0       0       1,254                                                    

  G3a                0              21           **70**                  1                                               0       0       92                                                       

  G3b                0              0            1                       **13**                                          0       0       14                                                       

  G4                 0              0            0                       6                                               **6**   0       12                                                       

  G5                 0              0            0                       0                                               0       **1**   1                                                        

  Total                             119          1,224                   112                                             20      6       1       1,482                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI, confidence interval; See [Table 1](#T1){ref-type="table"}.

###### Prevalence of reduced eGFR (\<60 mL/min/1.73 m^2^) based on the five equations, stratified by age group and sex^\*^
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  Age (yr)           Number (%) of subjects with reduced eGFR by each equation               
  ------------------ ----------------------------------------------------------- ----------- -----------
  MDRD                                                                                       
   30--39            6 (2.2)                                                     2 (1.6)     4 (2.7)
   40--49            17 (4.1)                                                    8 (3.5)     9 (4.9)
   50--59            46 (10.6)                                                   21 (10.7)   25 (10.6)
   60--69            45 (15.6)                                                   17 (12.4)   28 (18.4)
   70--79            25 (33.8)                                                   10 (27.8)   15 (39.4)
   Total             139 (9.4)                                                   58 (8.0)    81 (10.7)
  LM~revised~                                                                                
   30--39            2 (0.7)                                                     1 (0.8)     1 (0.7)
   40--49            6 (1.5)                                                     2 (0.9)     4 (2.2)
   50--59            24 (5.6)                                                    17 (8.7)    7 (3.0)
   60--69            53 (18.3)                                                   29 (21.2)   24 (15.8)
   70--79            34 (45.9)                                                   16 (44.4)   18 (47.4)
   Total             119 (8.0)                                                   65 (9.0)    54 (7.1)
  CKD-EPI~Cr~                                                                                
   30--39            2 (0.7)                                                     1 (0.8)     1 (0.7)
   40--49            6 (1.5)                                                     2 (0.9)     4 (2.2)
   50--59            16 (3.7)                                                    9 (4.6)     7 (3.0)
   60--69            34 (11.8)                                                   17 (12.4)   17 (11.2)
   70--79            25 (33.8)                                                   10 (27.8)   15 (39.5)
   Total             83 (5.6)                                                    39 (5.4)    44 (5.8)
  CKD-EPI~CysC~                                                                              
   30--39            2 (0.7)                                                     0 (0.0)     2 (1.4)
   40--49            1 (0.2)                                                     1 (0.4)     0 (0.0)
   50--59            7 (1.6)                                                     5 (2.6)     2 (0.8)
   60--69            14 (4.8)                                                    9 (6.6)     5 (3.3)
   70--79            11 (14.9)                                                   7 (19.4)    4 (10.5)
   Total             35 (2.4)                                                    22 (3.0)    13 (1.7)
  CKD-EPI~Cr-CysC~                                                                           
   30--39            2 (0.7)                                                     1 (0.8)     1 (0.7)
   40--49            0 (0.0)                                                     0 (0.0)     0 (0.0)
   50--59            7 (1.6)                                                     7 (3.6)     0 (0.0)
   60--69            15 (5.2)                                                    9 (6.6)     6 (3.9)
   70--79            15 (20.3)                                                   7 (19.4)    8 (21.1)
   Total             39 (2.6)                                                    24 (3.3)    15 (2.0)

^\*^GFR categories G3a-G5 correspond to GFR \<60 mL/min/1.73 m^2^.

Abbreviations: See [Table 1](#T1){ref-type="table"}.

[^1]: ^\*^Misuk Ji and Yoon-Hee Lee contributed equally to this work.
